NCT00651378终止4 期
An Open-Label, Randomized, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of "Switching" to Rosuvastatin 10 mg Daily Versus Atorvastatin 10 mg Daily With Ezetimibe 10 mg Daily Versus Doubling the Dose of Atorvastatin to 20 mg Daily in Subjects With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease or Diabetes Mellitus Who Have Not Achieved Study Target LDL-C Goal While Dosing With Atorvastatin 10 mg Daily
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 87
- 主要终点
- Percent change in LDL-C level from baseline to the study endpoint.
研究概览
简要总结
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20 mg/d is more effective in achieving goal LDL-cholesterol of <2.5 mmol/L. Treatment phase is 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years to 75 years of age;
- •Stabilized on atorvastatin 10 mg daily and by subject reported history had taken at least 80% of daily doses for the 4 weeks preceding Visit 1;
- •LDL-C concentration greater than or equal to 2.5 mmol/L to less than or equal to 160 mg/dL (less than or equal to 4.1 mmol/L) based on blood specimens taken at Visit 1, using the Friedewald calculation as described in the Protocol,Section 8.
- •(The lipid profiles at Visit 3 (baseline) and all subsequent visits were kept "blinded" until data analysis);
- •Triglyceride concentration of less than 350 mg/dL (less than 3.99 mmol/L) based on blood specimens taken at Visit 1;
- •Documented atherosclerotic disease, CHD, or diabetes mellitus;
- •Liver transaminases (ALT, AST) less than 50% above the upper limit of normal, with no active liver disease, and CPK less than 50% above the upper limit of normal as tested in blood specimens taken at Visit 1;
- •Clinical laboratory tests (CBC, blood chemistries, urinalysis) taken at Visit 1 must have been within normal limits or clinically acceptable to the Investigator;
- •Had been previously prescribed a cholesterol lowering diet and exercise program at least 4 weeks prior to Visit 1 and had been advised to continue the same diet and exercise program during the study;
- •Reported a stable weight history for at least 4 weeks prior to randomization at Visit 3 (baseline visit);
- •Women receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral contraceptives, must have been maintained on a stable dose and regimen for at least 8 weeks and willing to continue the same regimen for the duration of the study;
- •Women of childbearing potential (included women who were less than 1 year postmenopausal and women who became sexually active) must have been using an acceptable method of birth control (for example, hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or been surgically sterilized (for example, hysterectomy or tubal ligation).
- •Free of any clinically significant diseases other than hyperlipidemia, CHD, or diabetes mellitus that would interfere with study evaluations;
- •Understood and were able to adhere to the dosing and visit schedules, and demonstrated their willingness to participate in the study and comply with its procedures by signing a written informed consent.
排除标准
- •Consumption greater than 14 alcoholic drinks per week. (A drink is: a can of beer [1/2 pint or 250 ml], glass of wine, or single measure of spirits);
- •Any condition or situation which, in the opinion of the Investigator, might have posed a risk to the subject or interfered with participation in the study;
- •Body mass index (BMI) >= 35 Kg/m^2 at Visit 2 (Screening);
- •Women who were pregnant or nursing;
- •Failure to observe the designated washout periods for any of the prohibited medications
研究组 & 干预措施
Double Atorvastatin
Active Comparator
干预措施: Double Atorvastatin (Drug)
Rosuvastatin
Experimental
干预措施: Rosuvastatin (Drug)
Ezetimibe + Atorvastatin
Active Comparator
干预措施: Ezetimibe + Atorvastatin (Drug)
结局指标
主要结局
Percent change in LDL-C level from baseline to the study endpoint.
时间窗: 6 weeks
次要结局
- Percent changes from baseline to the end of treatment in the concentrations of total cholesterol (TC), non-HDL-C, apo B, triglycerides (TG), HDL-C, LDL-C/HDL-C ratio, and TC/HDL-C ratio.(6 weeks)
- Adverse events, laboratory test results, vital signs.(Throughout study)
研究者
相似试验
已完成
3 期
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)AtherosclerosisHypercholesterolemiaNCT00651404Organon and Co137
已完成
4 期
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)AtherosclerosisHypercholesterolemiaNCT00653796Organon and Co148
已完成
3 期
Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)HypercholesterolemiaNCT00654095Organon and Co146
已完成
4 期
Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)HypercholesterolaemiaAtherosclerosisNCT00653835Organon and Co153
已完成
3 期
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)HypercholesterolemiaNCT01370603Organon and Co328